Endogenous, nontelomeric reverse transcriptase (RT) is encoded by two classes of repeated elements: retrotransposons and endogenous retroviruses. Expression of RT-coding genes is generally repressed in differentiated nonpathological tissues, yet is active in the mammalian germ line, embryonic tissues and tumor cells. Nevirapine is a non-nucleoside RT inhibitor with a well-characterized inhibitory activity on RT enzymes of retroviral origin. Here, we show that nevirapine is also an effective inhibitor of the endogenous RT in murine and human cell lines. In addition, progenitor and transformed cells undergo a significant reduction in the rate of cell growth upon exposure to nevirapine. This is accompanied by the onset of differentiation, as depicted in F9 and C2C7 progenitor cells cultures in which nevirapine triggers the expression of differentiation-specific markers. Consistent with this, an extensive reprogramming of cell cycle gene expression was depicted in nevirapine-treated F9 cultures. Furthermore, nevirapine exposure rescued the differentiation block present in acute myeloid leukemia (AML) cell lines and primary blasts from two AML patients, as indicated by morphological, functional and immunophenotypic assays. The finding that an RT inhibitor can modulate cell proliferation and differentiation suggests that RT may represent a novel target in the development of therapeutical approaches to neoplasia.
Introduction
Retrotransposons are mobile elements abundantly represented in eucaryotic genomes, which retrotranspose via an RNA intermediate (Ostertag and Kazazian, 2001) . Retrotransposition events are mediated by a reverse transcriptase (RT) activity encoded by a gene harbored within the elements of many repeated families. RT activity is historically associated with replication of infective retroviruses (Baltimore, 1970; Temin and Mizutani, 1970 ), yet a large body of work has been carried out to pinpoint the function of the endogenous RT in cells and tissues. Several lines of evidence contribute to the hypothesis that, on the one hand, the retroviral/retrotransposon machinery plays a role in embryonic development; on the other hand, the unscheduled activation of retrotransposon integration in differentiated cells may facilitate cell transformation.
In support of a role of RT in early development, retrotransposons and retroviral genes are highly expressed in the mammalian germ line (Ostertag and Kazazian, 2001) , early embryos (Poznanski and Calarco, 1991; Packer et al., 1993) and embryonic tissues (Mwenda, 1993) . Murine spermatozoa are also endowed with a functional RT activity, able to retrotranscribe exogenous RNA molecules into cDNA copies that can then be delivered to embryos during fertilization (Giordano et al., 2000) . A similar RT activity is present in mouse cleavage embryos (CP, IS, EM, RL and CS, submitted) . In placenta, retroviral genes have contributed an important function by providing the env gene product, which has become a constitutive component of placenta (Mi et al., 2000) .
Retroelement mobilization is also implicated in a wide spectrum of pathologies including tumors (Miki, 1998; Ostertag and Kazazian, 2001) . Consistent with this, high expression of the cellular RT gene has been detected in transformed cells (Deragon et al., 1990; Martin, 1991; Martin and Branciforte, 1993) compared to the low level detected in nonmalignant, differentiated cells (Kiessling and Goluian, 1979; Salganick et al., 1985; Medstrand and Blomberg, 1993; Banerjee and Thampan, 2000 ).
Here we have tested the effect of a well-characterized RT inhibitor, nevirapine, in normal and transformed mammalian cells. We report that exposure to nevirapine is associated with decreased cell growth rate in a variety of murine and human tumorigenic cell lines. Reduced cell growth is accompanied by the onset of differentiation in murine C2C7 myogenic progenitor cells and in multipotent F9 teratocarcinoma cells. Moreover, human acute myeloid leukemia (AML) cell lines and primary blasts from two AML patients blocked at different differentiation stages all undergo differentiation in response to nevirapine exposure. These results suggest that deregulated RT activity may be associated with cell transformation and suggest that RT-inhibiting drugs may be employed to modulate cell growth in the clinical therapy of tumors.
Results

Nevirapine inhibits the growth of murine progenitor cell lines
As a first step to test the effect of an anti-RT drug in mammalian cells, we followed up the growth rate and cell cycle progression in cultures exposed to nevirapine, a highly specific inhibitor of RT (Merluzzi et al., 1990 ), compared to nonexposed controls. For these experiments, we selected a panel of progenitor and tumorigenic cell lines of murine (groups i-iv) and human (groups v-ix) origin, including: (i) C2C7 myogenic precursor cells; (ii) NIH/3T3 embryo fibroblasts; (iii) multipotent F9 teratocarcinoma; (iv) L929 fibrosarcoma; (v) HT-29 colon carcinoma; (vi) MCF-7 breast carcinoma, expressing the estrogen receptor (ER+); (vii) MDA-231 breast carcinoma, negative for ER expression (ERÀ); (viii) U343 Mg glioma and (ix) Saos-2 osteosarcoma. Cells were cultured with or without nevirapine; aliquots were withdrawn at regular intervals and counted. As shown in Figure 1 , exposure to nevirapine yields a decrease in the rate of proliferation in all cell lines. Some cell type-specific differences were observed in the response to the drug: F9 teratocarcinoma cells showed the highest response, with a 2.5-fold reduction in the proliferation rate after the first 48-72 h, and fivefold after 120 h of exposure. A comparable effectiveness was depicted in HT-29 colon carcinoma cells. Saos-2 osteosarcoma cells were the most slowly responsive type, and only after 5 days of exposure did the growth rate begin to decrease compared to control cultures. In our experiments, nevirapine did neither cause nonspecific cell death nor apoptosis in any tested cell line, as indicated by FACS measurement of cells with dense granularity and hypodiploid DNA content: over 85% of exposed cells in all cell lines remained viable at all times (data not shown). Thus, the decrease in cell growth rather reflects a progressive withdrawal from the cell cycle. Indeed, FACS analysis depicted changes in the cell cycle profile of several cell types: as shown in Figure 2a , cells with a G0/G1 DNA content accumulated in NIH/3T3, HT-29, MCF-7 and U343 Mg cultures after 72 h of nevirapine treatment, whereas at these same times control samples displayed cell cycle profiles typical of proliferating cultures. This was accompanied by a substantial decrease in cyclin D1 levels in NIH/3T3, HT-29, MCF-7 (Figure 2b ) and U343 Mg glioma (data not shown) cultures exposed to nevirapine compared to nonexposed controls.
An endogenous RT activity is present in murine and human cell lines
We next tested the presence of active RT, the enzyme targeted by nevirapine, in murine and human cell lines that displayed an effect in response to the drug in Figure 1 , as well as in human myeloid leukemia HL60, NB4, R4 and Kasumi-1 cell lines. In a first set of experiments, the endogenous RT enzymatic activity present in mammalian cells was functionally tested in a PCR-based in vitro assay. To that aim, we used cell lysates as RT sources and purified MS2 phage RNA as template; after incubation, the synthesis of MS2 cDNAs was assessed by direct PCR. As shown in Figure 3a , a DNA product of the expected size was amplified, with variable intensity, with all tested cell lysates (lanes 1-13), indicating that the input RNA had been reversetranscribed. No amplification product was observed when MS2 RNA (lane 14) or cell lysate (lane 16) were omitted. When cell lysates were preincubated with nevirapine, cDNA synthesis was inhibited in a dosedependent manner (lanes 20-22). Thus, an endogenous RT is active in a variety of murine and human cells and is sensitive to nevirapine inhibition.
Western immunoblotting assays were also carried out to examine the distribution of RT proteins in cell types of various sources. Anti-RT antibody was employed to analyse extracts from whole cells (WCE), or purified nuclei, from F9, NIH/3T3, MCF-7, MDA-231, NB4 and HL60 cell lines, and WCE from primary blasts of an acute myeloid leukemia patient (AML #1). As shown in Figure 3b , two major groups of reactive proteins were consistently detected: a group of faster mobility, with two prominent bands of about 55 and 66 kDa, and a slowly migrating band in the 150 kDa region. The two fast-migrating bands are present in WCE and nuclei of all analysed samples, and display a comparable electrophoretic mobility to that reported for RT proteins of retroviral origin (Di Marzo Veronese et al., 1986) . The slower-migrating band displays an electrophoretic mobility compatible with the expected size of the three conserved domains encoded by ORF2 of the L1 element (Ostertag and Kazazian, 2001 ) and may represent an unprocessed product. This protein is more easily detected in nuclear extract compared to WCE, and is more abundant in F9 compared to other cell types; weaker, though detectable, signals were also seen in MCF-7, MDA-231 and NB4 nuclear extract. The high molecular anti-RT reactive bands truly represent nuclear products, and do not reflect cytoplasmic contamination, as indicated by the absence of a-tubulin signal. In summary, the high molecular weight RT species is concentrated in nuclei with differential abundance in different cell types, while RT proteins of canonical size are present in all cell types.
Exposure to nevirapine promotes differentiation in progenitor cell lines
Since nevirapine inhibits cell proliferation, we wondered whether the process of differentiation was concomitantly influenced. To this end, we used model cell systems capable of undergoing differentiation in vitro with well-characterized patterns. We first examined murine C2C7 myogenic satellite cells, which proliferate as mononucleated myoblasts in the presence of growth factors, yet exit the cell cycle when placed in differentiation medium and differentiate to form multinucleated myotubes that Figure 1 Nevirapine inhibits proliferation in murine and human cell lines. Cells were cultured with (solid line) and without (DMSO, dashed line) nevirapine. The proliferation rate is expressed as the ratio of counted cells at the indicated times relative to the initial number of seeded cells, taken as 1. Points represent the mean value and bars the s.d. from at least three independent assays for all cell types RT inhibitior influences cell growth and differentiation R. Mangiacasale et al express muscle-specific genes. In this cell line, therefore, the onset of differentiation implies cell cycle exit and growth arrest. In the experiments in Figure 1 , nevirapine inhibited the growth of C2C7 myoblasts. C2C7 cells were cultured with or without nevirapine for 90 h, during which control cultures reached a saturation density -a critical factor underlying fusion of myoblasts to form myotubes -and then transferred to differentiation medium for 48 h. Light-field microscopy scoring (n ¼ 300 cells from randomly selected fields) revealed that the ratio between multinucleated myotubes (i.e. cells with more than three nuclei) and mono/binucleated cells was about 1 : 1 in nevirapine-treated compared to 1 : 2 in untreated samples. Cells monolayers were further analysed by IF to myosin heavy chain (MHC), a late marker of muscle differentiation. In control cultures kept in differentiation medium for 48 h, multinucleated MHC-containing myotubes were thin and markedly smaller (Figure 4c ) than in RT inhibitior influences cell growth and differentiation R. Mangiacasale et al cultures pretreated with nevirapine ( Figure 4d ), despite the lower cell density in nevirapine-treated compared to control plates. Isolated myoblasts were mostly MHC-negative in control cultures (Figure 4a ), whereas myosin synthesis was already activated in isolated myoblasts in nevirapine-treated plates ( Figure 4e ). We next asked whether nevirapine also triggered differentiation in teratocarcinoma F9 cells, which were highly sensitive to growth inhibition by the drug (Figure 1 ). Untreated F9 cells have a rounded shape and tend to form aggregates during growth ( Figure 5a ). When exposed to retinoic acid (RA) for 72 h, characteristic signs of morphological differentiation become apparent (Figure 5e ), including a decreased tendency to form aggregates, increased adhesiveness and reorganization of the cell surface with the appearance of a differentiated morphology, in agreement with previous reports (Ross et al., 1994) . Similar changes were observed in nevirapine-exposed cultures ( Figure 5i ). The morphological reorganization was accompanied by an increased synthesis of collagen type IV(a1) chain (Figure 5k ), a marker of differentiation induced in response to RA (Figure 5g ; Rogers et al., 1990; Ross et al., 1994) , synthesized at low levels in control cultures ( Figure 5c ). Together, the results in Figures 4 and 5 indicate that nevirapine triggers or facilitates the onset of differentiation in two different cell types.
Altered expression of cell cycle regulatory genes in nevirapine-treated F9 cells
To assess whether the ability of nevirapine to influence growth and differentiation reflected changes in expression of specific genes, RNA was extracted from control, nevirapine-and RA-exposed F9 cells and subjected to semiquantitative RT-PCR analysis. We examined a set of genes encoding D-type cyclins, growth inhibitors, modulators of apoptosis and housekeeping proteins. Representative panels are shown in Figure 6a and results are quantified in Figure 6b . Most significant variations were recorded for the cyclin D1 gene, which was downregulated by sevenfold, whereas p16
INK4a , encoding the major antagonist of D-type cyclins, was upregulated by nearly eightfold in nevirapine compared to nonexposed F9 cultures. Upregulation, albeit quantitatively less pronounced (about threefold), was also recorded for p27
Kip 1 (which critically modulates proliferation in response to cell shape and adhesion), Rb-2/ p130 (which is associated with withdrawal from the proliferative cycle) and Bcl-2 (which can facilitate growth arrest in some cell types) (Chou et al., 2000) . Cyclin D3 expression was instead downregulated in response to nevirapine. In general, the same set of genes was also responsive to RA, though subtle differences were observed: for example, RA was consistently more effective in upregulating p21
Cip 1 , Rb-1/pRb, Rb-2/p130 and Bcl-2, whereas nevirapine showed a greater effectiveness in modulating cyclin D1, D3 and p27
Kip1 mRNA RT inhibitior influences cell growth and differentiation R. Mangiacasale et al levels ( Figure 6a ). These changes are specific because expression of housekeeping genes (b-actin, GAPDH), as well as p53, was unaffected.
Nevirapine treatment induces AML blast differentiation
We next sought to establish whether the observed effects of nevirapine on differentiation of progenitor cells could be extended to human leukemia cells. We initially analysed the effect of nevirapine in the acute promyelocytic NB4, expressing the t(15;17) oncoprotein PML/RAR, responsible for the differentiation block present in these blasts (Grignani et al., 1998; Di Croce et al., 2002) , and the AML HL60 cell lines, in comparison with their known sensitivity to RA-induced granulocytic differentiation (Breitman et al., 1980; Lanotte et al., 1991) . After 5 days of nevirapine treatment, the appearance of cells with a myelomonocytic-like morphology was evident in both cell lines (Figure 7 ), whereas cells with metamyelocyte-like morphology were induced by 1 mm RA, as reported ( Figure 7 and data not shown). We then analysed the expression of the three surface antigens CD11b, CD14 and CD15, after 4 days of culture in the presence of RA or nevirapine (Table 1 ). The induction of CD11b is associated with granulocytic differentiation, CD14 is considered a monocytic-specific antigen and CD15 is a myelomonocytic antigen. Simultaneous induction of CD14 and CD11b relates to monocytic differentiation. Consistent with the induction of granulocytic differentiation, RA treatment increased the levels of CD11b and CD15, but not CD14, in both cell lines. In nevirapine-treated NB4 and HL60 cells, a strong induction of expression of CD15, and, to a lesser degree, CD11b and CD14 markers was detected. Thus, nevirapine treatment induces expression of myelomonocytic differentiation markers, consistent with the morphological studies. Nevirapine treatment also increased the number of positive cells in the NBT dye reduction assay by about 2.0-3.5-fold (Table 2 ). RT inhibitior influences cell growth and differentiation R. Mangiacasale et al
The effect of nevirapine was further analysed in myeloid leukemia cells poorly sensitive to RA-induced granulocytic differentiation, such as the Kasumi-1 cell line expressing the t(8;21) translocation product AML1/ ETO, and in primary blasts from two AML patients (Ferrara et al., 2001) . Nevirapine treatment, though not actually arresting proliferation, induced a modest yet constant accumulation of cells in the G1 phase of the cell cycle (data not shown). In addition, both Kasumi-1 cells and primary AML blasts responded to nevirapine treatment by triggering differentiation, as revealed by the induction of: (i) morphological changes related to myelomonocytic differentiation (Figure 7) , consisting of chromatin condensation with initial nuclear segmentation, decreased nuclear/cytoplasmic ratio, decreased cytosolic basophilia and appearance of a paranuclear Golgi region (specific granules were evident in the case of AML#1); (ii) functional changes, indicated by increased NBT positivity (Table 2 ) and (iii) changes in the expression of myeloid immunophenotypic markers CD11b, CD14 and CD15 (Table 1 and data not shown). The extent of induction of myeloid differentiation features in primary AML blasts was comparable to that detected in NB4 and HL60 cells.
Discussion
In earlier work, high levels of expression of the cellular retroposon RT gene (Deragon et al., 1990; Martin, 1991; Martin and Branciforte, 1993) , as well as endogenous retroviruses (Friedlander and Patarca, 1999) , were detected in tumor cells, suggesting that expression of genes of retroposon/retroviral origin correlates with tumorigenesis. Here we report that the rate of cell growth is downregulated, while differentiation is facilitated, in normal and transformed cell lines of murine and human origin cultured in the presence of nevirapine, a specific inhibitor of RT activity. To the best of our knowledge, the present data provide the first evidence that an inhibitor of the endogenous cellular RT can concomitantly modulate the growth rate and the differentiation program in mammalian cultured cells.
Nevirapine is a specific RT inhibitor widely used in AIDS therapy, and is reported to exert a highly selective , 1986) . We show here that RT enzymes present in mammalian noninfected cell lines are actually sensitive to inhibition by nevirapine in a functional assay in vitro. In vivo, this is associated with reduced cell growth within only 3-5 days of treatment. The simplest interpretation of the phenomena depicted in proliferating cells is that nevirapine acts by inhibiting the endogenous RT in vivo.
The rapid response depicted in our experiments rules out the possibility that nevirapine targets telomerase-associated RT (Tert). Drug-mediated telomerase inhibition in cancer cells has been reported to reduce proliferation, concomitant with the appearance of senescence hallmarks, after a long period (about 120 days) of treatment (Damm et al., 2001) . Furthermore, neither differentiation nor organogenesis are affected in homozygous telomerase-null mice (Blasco et al., 1997) , whereas, in our experiments, cell growth and morphology are affected. Based on these observations, the possibility that Tert is targeted by nevirapine can be reasonably ruled out. Nevirapine-dependent inhibition of proliferation in murine and human cells was accompanied, in several cases, by a significantly delayed progression through the G0/G1 phase of the cell cycle. Consistent with this, a substantial decrease in the levels of cyclin D1, which acts as a critical molecule in the commitment to enter the cell cycle, was induced. This suggests that nevirapine exposure modulates the expression of one or more key genes in the cell division program, with an ensuing decrease of proliferation and/or the onset of differentiation. The ability of nevirapine to induce changes in gene expression was investigated more extensively in F9 cell cultures. F9 cells are well known to reprogram the expression of cell cycle genes and undergo differentiation in response to genome-remodeling agents such as histone acetylases (Kawasaki et al., 1998) and RA (reviewed by Darrow et al., 1990) . In our study, we selected a panel of genes that can be regarded as markers of the proliferative or differentiating states. Indeed, the inhibition of cell growth and the appearance of differentiation, as revealed by morphological changes and activation of collagen synthesis, in nevirapinetreated F9 cultures were consistent with changes in the expression of key genes. In particular, expression of genes for D-type cyclins was downregulated, consistent with the results from other cell types; conversely, growth-inhibitory genes including p16
INK4a
, Rb-2/p130 and p27
Kip 1 were upregulated. Most nevirapine-responsive genes also respond to RA (Kawasaki et al., 1998; Li et al., 1999; and this paper) , although the amplitude of the response to each drug may vary for specific genes. To further substantiate the ability of nevirapine to modulate expression of genes governing proliferation and differentiation, we examined C2C7 myogenic cells, in which the onset of differentiation implies cell cycle exit. Indeed, myogenic cultures proved able to differentiate more effectively after pre-exposure to nevirapine compared to nonexposed controls.
We further sought to verify whether nevirapine also promoted differentiation of primary neoplastic human cells, as it does in model cell lines. Primary blasts from AML patients represent an easily accessible and very handy source of human neoplastic cells, and important We do not know at this stage how nevirapine produces the observed effects on proliferation and differentiation. It is tempting to speculate that nevirapine, by inhibiting the endogenous RT, modulates the level of endogenous retrotranscription, which in turn influences the activity of proliferation and/or differentiation regulatory genes. RT activity may be deregulated in transformed cells. Retrotransposition has far-reaching effects in the genome and various mechanisms are reported to underlie its effects on gene expression: (i) insertional mutagenesis of retroelements, yielding the creation of new genes (Nekrutenko and Li, 2001) , or, on the contrary, the functional 'knockout' of pre-existing ones (reviewed by Kazazian, 1998) ; (ii) activation of existing genes, by providing new promoters in the sense (Ferrigno et al. 2001) and antisense (Speek, 2001) orientation (Ting et al., 1992) ; (iii) rearrangement within regulatory regions, providing either target DNA sites for transcription factors (reviewed by Tomilin, 1999) ; hormone- (Norris et al., 1995; Babich et al, 1999) and RA receptor- (Islam et al., 1993) dependent enhancers, or novel splicing sites (Ashworth et al., 1990; FeuchterMurthy et al., 1993) . Recently, retrotransposons have been found to exert an epigenetic control on gene expression, thereby acting as epigenetic mediators of phenotypic variations (Morgan et al., 1999; reviewed by Whitelaw and Martin, 2001) . Although not all molecular steps are fully understood as yet, retrotransposons -depending on their own status of transcriptional competence -can modulate the expression of specific loci through a transcriptional interference-based mechanism.
The RT-PCR experiments reported here indicate that nevirapine elicits a response at the level of mRNA transcription and/or stability, although other levels of gene control may also be targeted. To pinpoint the specific mechanism(s) responsible for the reprogramming of growth and differentiation genes in nevirapinetreated cells, it will be important to analyse the global response at the genome level.
In the light of the present results, the possibility may be envisaged that antiretroviral drugs be tested in antitumor therapy, although it must be recalled that nevirapine can exert toxic effects in a proportion of AIDS patients, and the risk of developing necrolysis of the epidermis has been reported (Cattelan et al., 2001; Fagot et al., 2001) . On the other hand, however, clinical studies indicate a reduced incidence of AIDS-related cancers in patients treated with highly active antiretroviral therapy (HAART) (Tirelli and Bernardi, 2001 ). Although these data may indicate a stronger reaction against cancer of the improved immune system of HAART-treated patients, they may also reflect a direct inhibitory effect of HAART on the highly active endogenous retroviral system in tumor cells.
The central role of RT at the intersection between normal development and cancer was Temin's trailbreaking prediction over 30 years ago (Temin, 1971) . The increasingly emerging view now suggests that endogenous RT is not a mere parasitic function encoded by 'selfish' DNA elements, but rather an active genomeshaping force, leading to the emergence of novel phenotypes (Brosius and Tiedge, 1996) .
Materials and methods
Cell cultures
C2C7 myoblasts (Yaffe and Saxel, 1977) were cultured in DMEM supplemented with 20% fetal bovine serum (FBS); NIH/3T3 (ATCC CRL-1658). Other cell lines, including F9 (ATCC CRL-1720), L929 (ATCC CCL-1), Saos-2 (ATCC HTB-85) and human glioma U-343 Mg cells (Libermann et al., 1987) , kindly given by Dr B Westernmark (Department of General Pathology, University of Uppsala, Sweden), human colon carcinoma HT-29 cells, provided by Professor G Sica (Institute of Histology, Universita`Cattolica del S Cuore, Rome, Italy), MCF-7 (ATCC HTB-22) and MDA-231 (ATCC HTB-26), were grown in DMEM containing 10% FBS. Pure nevirapine was kindly provided by Boehringer Ingelheim, or purified by Dr Antonello Mai (Department of Pharmacology, University 'La Sapienza', Rome) and dissolved in DMSO. Dose-response experiments in NIH/3T3, F9, L929, HT-29 and U343 cell lines depicted the maximal effectiveness in growth suppression with 350-450 mm nevirapine, an intermediate response with 200 mm, and no suppressive effect below 100 mm. Studies presented in this paper were generally performed with 400 mm unless indicated otherwise. Cells were plated at the initial density of 20-50 Â 10 3 cells/35 mm diameter plate, depending on the cell type. After 5-6 h, when cells were adherent, nevirapine, or the same DMSO volume (0.005%, controls) were added. Parallel F9 samples were cultured with 10 À7 m RA (Ross et al., 1994) . Cells were harvested at regular intervals and counted in a ZM Coulter Counter (two countings per sample). Cell viability was assessed using the trypan blue dye exclusion method in a Burker chamber. For cell cycle analysis, cells were incubated in PBS containing 50 mg/ml propidium iodide (Sigma) and 50 mg/ml ribonuclease A; the cell cycle phase distribution was calculated on the basis of the DNA content of cells using the Multicycle or the WinMDI software in a FACStar Plus flow-cytometer (Beckton-Dickinson) (10 000 events/sample). Apoptosis was determined by quantifying the fraction of cells with high granularity and hypodiploid DNA content in biparametric analyses as described (Ciciarello et al., 2001 ).
Western and RT activity assays
Whole cells or purified nuclei, prepared as in Hewish and Burgoyne (1973) , were lysed in 20 mm Tris (pH 7.5) containing 300 mm sucrose, 60 mm KC1, 15 mm NaC1, 5% (v/v) glycerol, 2 mm EDTA, 1% Triton X-100 (v/v), 1 mm PMSF, 2 mg/ml aprotinin, 2 mg/ml leupeptin and 0.2% deoxycholate (w/v) for 20 min on ice. Extracts were fractionated through 4-12% gradient SDS-PAGE. Western immunoblotting assays were carried out using mouse monoclonal anticyclin D1 CL DCS-6 (Sigma); mouse monoclonal anti-RT antibody, or rabbit IgGpurified polyclonal anti-RT antibody (both from Intracel Corp.,); mouse monoclonal anti-a tubulin, Clone B-5-1-2, ascite fluid (Sigma); mouse monoclonal antiactin C1 AC-40 (Sigma) and HRP-conjugated anti-IgG secondary antibody (Biorad, 1 : 20 000 dilution). Signals were revealed using the ECL kit (Amersham Pharmacia Biotech). To assay RT activity, 10 4 -10 6 cells were lysed in 20 ml ice-cold lysis buffer (10 mm Tris-Hcl pH 7.5, 1 mm MgCl 2 , 1 mm EGTA, 0.1 mm PMSF, 5 mm b-mercaptoethanol, 0.5% CHAPS, 10% glycerol). After three freeze-and-thaw cycles, cells were incubated for 30 min on ice and centrifuged for 30 min at 14 000 r.p.m. at 41C. RT activity was tested using a Thermoscript RT-PCR system (Invitrogen) in 20 ml reactions containing 10 ng of MS2 phage RNA (Roche Diagnostics), 50 mm Tris acetate (pH 8.4), 75 mm K acetate, 40 mm Mg acetate, 5 mm DTT, 1 mm of four nucleotide triphosphate mix, 2 U of RNaseOUT, 30 pmol of MS2 reverse primer (see below) and substituting commercial RT with cell-free extract (12 mg total protein). Reaction mixtures were incubated at 551C for 1 h followed by 5 min at 851C. A 1 ml volume of Escherichia coli RNaseH (2 U/ml) was added to each sample and further incubated at 371C for 20 min. Control reactions were set up by omitting cell extract (negative controls), or adding 1 ml of ThermoScript RT (Invitrogen) (15 U/ml, positive controls). A 2 ml volume from each reaction was mixed with 30 pmol each of forward (5 0 -TCCTGCTCAACTTCCTGTCGAG-3 0 ) and reverse (5 0 -CAT-AGGTCAAACCTCCTAGGAATG-3 0 ) MS2 primers and PCR-amplified using the ThermoScript RT-PCR kit (Invitrogen). PCR conditions were as follows: 951C for 2 min, followed by 28 cycles of 941C for 30 s, 581C for 45 s and 721C for 1 min. The amplification product is a 112-bp DNA fragment spanning positions 21-132 at the 5 0 end of the MS2 RNA (GenBank J02467). PCR products were fractionated through 1.5% agarose gel electrophoresis. In vitro assays of RT inhibition were performed in the same mixtures except that extracts were preincubated with various nevirapine doses for 45 min at 371C prior to adding the MS2 RNA template.
Cytological analysis and indirect immunofluorescence
C2C7 cells precultured in growth medium with or without nevirapine for 4 days were transferred to DMEM containing 2% FBS (differentiation medium). After 48 h, cells were examined by light-field microscopy and the ratio of multinucleated myotubes to mono-and binucleate cells was calculated. Parallel samples were fixed and immunostained using hybridoma-conditioned antimyosin antibody clone MF20 (Bader et al., 1982) , diluted 1 : 4 in PBS containing 3% BSA, revealed by a fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG antibody (Pierce 31569ZZ, 1 : 200 dilution). Nuclei were stained with Hoechst 33258 (1 mg/ ml in PBS) to visualize DNA. Morphological changes in F9 cultures were recorded in DMSO-(controls), nevirapine-or RA-exposed culture dishes using a Nikon Eclipse 300 inverted microscope with a 371C heated stage equipped with a Digital Camera (Nikon DXM 1200). Cells were processed for IF analysis with primary rabbit antibody to collagen type IV (a1) chain (AB756P, Chemicon International Inc.), followed by FITC-conjugated secondary antibody (SantaCruz Biotechnology, sc2090). Cell preparations were counterstained with 0.1 mg/ml DAPI for 10 min and mounted on glass slides in Vectashield (Vector). Cell preparations were examined under an Olympus AX70 microscope equipped with epifluorescence and a CCD camera device (Photometrics).
RNA extraction and semiquantitative RT-PCR analysis
RNA was extracted using the RNAeasy kit (Qiagen) and routinely incubated with DNase I (Invitrogen) (1 U/mg RNA) for 15 min. cDNAs were synthesized using 300 ng of total RNA, oligo (dT) and the Thermoscript system (Invitrogen). A volume of 2 ml from each mixture was withdrawn and PCRamplified using the Platinum Taq DNA Polymerase kit (Invitrogen) in a Peltier Thermal Cycler PTC 200 (MJ Research) in the following conditions: 2 min at 941C, followed by 20-30 cycles at 941C for 30 s, 58-621C for 30 s, 721C for 1 min. To prevent PCR amplification from reaching a plateau and mask differences in gene expression, each gene was subjected to PCR assays in sequential series of 20-30 cycles, using RNA batches from at least three independent experiments. Expected amplification product sizes (in brackets), forward (fd) and reverse (rev) primers were as follows: Amplified products were fractionated through 1.4% agarose gels and Southern blotted. The specificity of the reaction was confirmed by hybridization with the following internal oligonucleotides:
b-actin, 5 0 -GGTACCACCATGTACCCAGG-3 0 ; GAPDH, 5 0 -GGGAAGCCCATCACCATCT-3 0 ; Cyclin D1, 5 0 -TTGACTGCCGAGAAGTTGTG-3 0 ; Cyclin D3, 5 0 -GAGATCAAGCCGCACATGCGGAA-GA-3 0 ; p21 After washing, filters were exposed to Fuji X-ray films and signal intensities were quantified by densitometric scanning of the bands.
Human AML cells
Leukemia cells were isolated from the peripheral blood of two informed, newly diagnosed AML patients, classified as AML-M2 (AML#1) or AML-M5 (AML#2) according to the French-American-British (FAB) classification (Bennett et al., 1985) , both presenting more than 90% blast count and enriched on Ficoll-Hypaque density gradient as described (Ferrara et al., 2001) . AML blasts, the acute promyelocytic leukemia NB4 cell line and the AML cell lines HL60 and Kasumi-1 were cultured in RPMI 1640 medium supplemented with 10% FCS and treated with 1 mm RA or 400 mm nevirapine. Viable cells were counted via the trypan blue exclusion method as described (Ferrara et al., 2001; Gottlicher et al., 2001) . Cell differentiation was evaluated using four assays: (i) evaluation of cellular morphology by light-field microscopy of WrightGiemsa-stained cytospins; (ii) FACS analysis of the cell cycle after incubation of cell suspensions with propidium iodide (Coulter Epics XL flow cytometer, Beckman); (iii) expression of cell surface antigens, after incubation of 0.5 Â 10 6 cell aliquots with antibodies directed to CD11b, CD14 and CD15, and flow cytometry quantification of signals in a Coulter Epics XL flow cytometer (Beckman); (iv) nitroblue tetrazolium (NBT) dye reduction assay: briefly, 2 Â 10 5 cells were resuspended in 200 ml of 1 mg/ml NBT (Sigma) in RPMI/ 2.5% FBS plus 3 m1 of 10 À3 m phorbol 12-myristate 13-acetate (Sigma). At least 500 morphologically intact cells were counted per experimental condition; the data were corrected for viability as measured by trypan blue exclusion.
